Diagnostics For All Set To Take The Field For Clinical Trials
This article was originally published in Start Up
Executive Summary
Not-for-profit start-up Diagnostics for All is set to begin a field trial in Kenya in March to evaluate a postage stamp-sized disposable diagnostic device to assess liver function in AIDS and TB patients. But the company eschews the notion that it's a charitable endeavor. Rather, it has crafted a licensing deal and business model that anticipates leveraging its not-for-profit work into a sustainable commercial First World business.
You may also be interested in...
Can Diseases of Poverty Pay?
Medicines to fight significant global health problems are scarce because the lack of commercial return trumps the fact that drug targets are well characterized and the required R&D investment is relatively inexpensive. The Gates Foundation hopes to create a more robust marketplace for global health medicines through non-dilutive funding. Gates money, plus Priority Review Vouchers and other creative tactics to ensure a market for these medicines may also persuade companies to develop drugs for long overlooked diseases such as malaria and tuberculosis. It's not yet clear whether these alternate funding schemes will prove attractive, but they may start making global health increasingly a part of business planning.
Venture Philanthropy: The New Venture Capital?
Non-profit organizations' growing support for industry drug development does more than fill a funding gap. It brings disease-knowledge, patient-access and an understanding of the end-market that few traditional VCs can offer.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”